Rhinorrhea, cough and fatigue in patients taking sitagliptin

Allergy, Asthma and Clinical Immunology

Volumn 6, Issue 1, 2010, Pages

  Baraniuk, James N ^a   Jamieson, Mary J ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b East Tennessee State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; SITAGLIPTIN;

ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CASE REPORT; COMPARATIVE STUDY; COUGHING; DISEASE DURATION; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; PEAK EXPIRATORY FLOW; RHINORRHEA;

EID: 79953005685     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/1710-1492-6-8     Document Type: Article

References (51)

1. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Mest HJ, Mentlein R, Diabetologia 2005 48 616 620 10.1007/s00125-005- 1707-5 15770466 (Pubitemid 40591214)
2. Januvia (sitagliptin) tablets. Anon, Circular Number 9762802 Merck & Co., Inc. Whitehouse Station, NJ 088893
3. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-nave patients with type 2 diabetes: comparison with metformin. Göke B, Hershon K, Kerr D, Calle Pascual A, Schweizer A, Foley J, Shao Q, Dejager S, Horm Metab Res 2008 40 12 892 5 10.1055/s-0028-1082334 18726829
4. Onglyza (saxagliptin) tablets. Anon, Circular Number 1256316 Bristol-Meyers Squibb, Princeton, NJ 08543 2009
5. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C, Vasc Health Risk Manag 2008 4 4 753 68 19065993
6. Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. Grouzmann E, Monod M, Landis B, Wilk S, Brakch N, Nicoucar K, Giger R, Malis D, Szalay-Quinodoz I, Cavadas C, Morel DR, Lacroix JS, FASEB J 2002 16 1132 1134 12039843
7. Neutral endopeptidase activity and concentration of sensory neuropeptide in the human nasal mucosa. Lacroix JS, Kurt AM, Pochon N, Bretton C, Lundberg JM, Deshusses J, Eur Arch Otorhinolaryngol 1995 252 465 468 10.1007/BF02114752 8719587 (Pubitemid 26003861)
8. Study of the enzyme peptidyl peptidase IV in nasal mucosa. Giger R, Nicoucar K, Kurt AM, Grouzman E, Lacroix JS, Schweiz Med Wochenschr Supple 2000 125 99S 101S
9. Implication of dipeptidylpeptidase IV activity in human bronchial inflammation and in bronchoconstriction evaluated in anesthetized rabbits. Landis BN, Grouzmann E, Monod M, Busso N, Petak F, Spiliopoulos A, Robert JH, Szalay-Quinodoz I, Morel DR, Lacroix JS, Respiration 2008 75 89 97 10.1159/000106267 17637510
10. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events. Ahren B, Best Pract Res Clin Endocrinol Metab 2009 23 4 487 98 10.1016/j.beem.2009.03.003 19748066
11. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL, Cochrane Database Syst Rev 2008 16 2 D006739
12. Guidelines for allergic rhinitis need to be used in primary care. Costa DJ, Bousquet PJ, Ryan D, Price D, Demoly P, Brozek J, Schunemann HJ, Bousquet J, Prim Care Resp J 2009 18 4 250 7 10.4104/pcrj.2009.00028
13. Global strategy for asthma management and prevention: GINA executive summary. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Fitzgerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ, Eur Respir J 2008 31 1 143 178 10.1183/09031936.00138707 18166595
14. Total IgE levels and asthma prevalence in the US population: Results from the National Heath and Nutrition Survey 2005-2006. Gergen PJ, Arbes SJ Jr, Calatroni A, Mitchell HE, Zeldin DC, J Allergy Clin Immunol 2009 124 3 447 53 10.1016/j.jaci.2009.06.011 19647861
15. Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is. Tumanan-Mendoza BA, Dans AL, Villacin LL, Mendoza VL, Rellama-Black S, Bartolome M, Ragual J, Flor B, Valdez J, J Clin Epidemiol 2007 60 6 547 53 10.1016/j.jclinepi.2006.06.017 17493508 (Pubitemid 46705480)
16. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Israili ZH, Hall WD, Annals of Internal Medicine 1992 117 3 234 242 1616218
17. The power of the placebo. Eccles R, Curr Allergy Asthma Rep 2007 7 2 100 4 10.1007/s11882-007-0006-2 17437679 (Pubitemid 46736330)
18. Mechanisms of the placebo effect of sweet cough syrups. Eccles R, Respir Physiol Neurobiol 2006 152 3 340 8 10.1016/j.resp.2005.10.004 16326149 (Pubitemid 44037503)
19. The placebo effect: plugging the nostrils of unmet needs. Baraniuk JN, Curr Allergy Asthma Rep 2009 9 2 149 52 10.1007/s11882-009-0022-5 19210905
20. Januvia and chronic cough-Medications.com. http://www.medications.com/se/ januvia/chronic-cough
21. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. Adler AI, Shaw EJ, Stokes T, Ruiz F, BMJ 2009 338 1328 9 10.1136/bmj.b1668
22. Information for Healthcare Professionals-Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm
23. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. Veken Van der P, Haemers A, Augustyns K, Curr Top Med Chem 2007 7 621 635 10.2174/156802607780091046 17352682 (Pubitemid 46488284)
24. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies. Skidgel RA, Erdös EG, Peptides 2004 25 521 525 10.1016/j.peptides.2003.12. 010 15134871 (Pubitemid 38591559)
25. Hereditary angioedema. Frank MM, J Allergy Clin Immunol 2008 121 2 Suppl 398 S401 10.1016/j.jaci.2007.07.057 18241690 (Pubitemid 351172427)
26. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Dicpinigaitis PV, Chest 2006 129 1 Suppl 169S 173S 10.1378/chest.129.1-suppl.169S 16428706 (Pubitemid 43265218)
27. Functional effects of phosphoramidon and captopril on exogenous neuropeptides in human nasal mucosa. Lacroix JS, Eur Arch Otorhinolaryngol 1995 252 2 83 5 7541210
28. Angiotensin- converting enzyme in the human nasal mucosa. Ohkubo K, Lee CH, Baraniuk JN, Merida M, Hausfeld JN, Kaliner MA, Am J Respir Cell Mol Biol 1994 11 2 173 80 8049077
29. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Erdös EG, Tan F, Skidgel RA, Hypertension 2010 55 2 214 20 10.1161/HYPERTENSIONAHA.109.144600 20065150
30. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T, Does MD, Brown NJ, J Allergy Clin Immunol 2007 120 403 408 10.1016/j.jaci.2007.04.012 17531305 (Pubitemid 47102380)
31. Influence of several peptidase inhibitors on the pro-inflammatory effects of substance P, capsaicin and collagenase. Damas J, Bourdon V, Liégeois JF, Simmons WH, Naunyn Schmiedebergs Arch Pharmacol 1996 354 662 669 8938667 (Pubitemid 26375995)
32. Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family. Ajami K, Abbott CA, Obradovic M, Gysbers V, Kähne T, McCaughan GW, Gorrell MD, Biochemistry 2003 42 694 701 10.1021/bi026846s 12534281 (Pubitemid 36133293)
33. Presence and release of SR-17 (chromogranin B (586-602)) in the porcine splenic nerve and its enzymatic degradation by CD26/dipeptidyl peptidase IV. Depreitere J, Durinx C, Wang Z, Coen E, Lambeir AM, Scharpé S, De Potter W, Nouwen EJ, Regul Pept 2002 106 71 79 10.1016/S0167-0115(02)00038-1 12047913 (Pubitemid 34607340)
34. Human nasal mucosal neutral endopeptidase (NEP): location, quantitation, and secretion. Ohkubo K, Baraniuk JN, Hohman RJ, Kaulbach HC, Hausfeld JN, Merida M, Kaliner MA, Am J Respir Cell Mol Biol 1993 9 557 567 8217197 (Pubitemid 2007531)
35. Neuropathology in rhinosinusitis. Baraniuk JN, Petrie KN, Le U, Tai C-F, Park Y-J, Yuta A, Ali M, VandenBussche CJ, Nelson B, Am J Respir Crit Care Med 2005 171 5 11 10.1164/rccm.200403-357OC 15477496 (Pubitemid 40051688)
36. Neuropeptide Y is a vasoconstrictor in human nasal mucosa. Baraniuk JN, Silver PB, Kaliner MA, Barnes PJ, J Appl Physiol 1992 73 1867 1872 1282125
37. Role of neuropeptide Y and dipeptidyl peptidase IV in regulation of Ewing's sarcoma growth. Kitlinska J, Kuo L, Abe K, Pons J, Yu M, Li L, Tilan J, Toretsky J, Zukowska Z, Adv Exp Med Biol 2006 575 223 229 full-text 16700526
38. M1 and M3 muscarinic antagonists inhibit human nasal glandular secretion in vitro. Mullol J, Baraniuk JN, Logun C, Mérida M, Hausfeld J, Shelhamer JH, Kaliner MA, J Appl Physiol 1992 73 2069 2073 1474087
39. Differential diagnosis of persistent nonallergic rhinitis and rhinosinusitis syndromes. Staevska MT, Baraniuk JN, Clin Allergy Immunol 2007 19 35 53 10.1027/0838-1925.19.1.35 17153006 (Pubitemid 46416241)
40. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. Ohnuma K, Munakata Y, Ishii T, Iwata S, Kobayashi S, Hosono O, Kawasaki H, Dang NH, Morimoto C, J Immunol 2001 167 6745 6755 11739489 (Pubitemid 33144164)
41. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Iwata S, Yamaguchi N, Munakata Y, Ikushima H, Lee JF, Hosono O, Schlossman SF, Morimoto C, Int Immunol 1999 11 417 426 10.1093/intimm/11.3.417 10221653 (Pubitemid 29121628)
42. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. Kobayashi H, Hosono O, Mimori T, Kawasaki H, Dang NH, Tanaka H, Morimoto C, J Rheumatol 2002 29 1858 1866 12233879 (Pubitemid 34988693)
43. The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Reinhold D, Kähne T, Steinbrecher A, Wrenger S, Neubert K, Ansorge S, Brocke S, Biol Chem 2002 383 1133 1138 10.1515/BC.2002.123 12437097 (Pubitemid 35215059)
44. Increased expression of plasma and CD4+ T lymphocyte costimulatory molecule CD26 in adult patients with allergic asthma. Lun SW, Wong CK, Ko FW, Hui DS, Lam CW, J Clin Immunol 2007 27 430 437 10.1007/s10875-007-9093-z 17525828 (Pubitemid 46906661)
45. Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M, Clin Exp Rheumatol 2001 19 673 680 11791639 (Pubitemid 34026831)
46. Patient satisfaction with antihypertensive therapy. Chen K, Chiou CF, Plauschinat CA, Frech F, Harper A, Dubois R, J Hum Hypertens 2005 19 793 799 10.1038/sj.jhh.1001899 15951740 (Pubitemid 41486142)
47. Aliskiren: an oral renin inhibitor for the treatment of hypertension. Lam S, Choy M, Cardiol Rev 2007 15 316 323 10.1097/CRD.0b013e31814852a4 18090068 (Pubitemid 350307641)
48. Central mechanisms IV: conscious control of cough and the placebo effect. Eccles R, Handb Exp Pharmacol 2009 187 241 62 full-text 18825344
49. Lowered serum dipeptidyl peptidase IV activity in patients with anorexia and bulimia nervosa. van West D, Monteleone P, Di Lieto A, De Meester I, Durinx C, Scharpe S, Lin A, Maj M, Maes M, Eur Arch Psychiatry Clin Neurosci 2000 250 86 92 10.1007/s004060070040 10853924 (Pubitemid 30326321)
50. Fluorine in pharmaceuticals: Looking beyond intuition. Muller K, Fach C, Diederich F, Science 2007 317 1881 1886 10.1126/science.1131943 17901324 (Pubitemid 47509426)
51. Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro- propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. Zhao K, Lim DS, Funaki T, Welch JT, Bioorg Med Chem 2003 11 207 215 10.1016/S0968-0896(02)00384-X 12470715 (Pubitemid 35418263)